Elevated serum thymus and activation-regulated chemokine (TARC/CCL17) relates to reactivation of human herpesvirus 6 in drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS).

1 Kauzman A, Quesnel-Mercier A, Lalonde B. Orofacial granulomatosis: 2 case reports and literature review. J Can Dent Assoc 2006; 72:325–9. 2 Campbell HE, Escudiet MP, Patel P et al. Review article: cinnamonand benzoate-free diet as a primary treatment for orofacial granulomatosis. Aliment Pharmacol Ther 2011; 34:687–701. 3 Giovannetti A, Mazzetta F, Cavani A et al. Skewed T-cell receptor variable b repertoire and massive T-cell activation in idiopathic orofacial granulomatosis. Int J Immunopathol Pharmacol 2012; 25:503– 11. 4 Al Johani KA, Moles DR, Hodgson TA et al. Orofacial granulomatosis: clinical features and long-term outcome of therapy. J Am Acad Dermatol 2010; 62:611–20. 5 McCartan BE, Healy CM, McCreary CE et al. Characteristics of patients with orofacial granulomatosis. Oral Dis 2011; 17:696– 704. 6 O’Neill ID, Scully C. Biologics in oral medicine: oral Crohn’s disease and orofacial granulomatosis. Oral Dis 2012; 18:633– 8. 7 Elliott T, Campbell H, Escudier M et al. Experience with anti-TNFa therapy for orofacial granulomatosis. J Oral Pathol Med 2011; 40:14–19. 8 Hegarty A, Hodgson T, Porter S. Thalidomide for the treatment of recalcitrant oral Crohn’s disease and orofacial granulomatosis. Oral Surg Oral Med Pathol Oral Radiol Endod 2003; 95:578–85. Funding sources: none.